Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

GlaxoSmithKline5,180 enrolled

Overview

The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.

Study Type

OBSERVATIONAL

Enrollment

5,180

Conditions

Asthma

Interventions

Fluticasone propionate/salmeterol combinationDRUG

Asthma subjects newly prescribed fluticasone propionate/salmeterol combination

Inhaled corticosteroidsDRUG

asthma subjects newly prescribed inhaled corticosteroids in clinical practice

Eligibility

Sex: ALLMin age: 12 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with asthma as determined by ICD-9 codes and asthma drug use * at least 12 years of age * treated with inhaled corticosteroids Exclusion Criteria: * Subjects with COPD or treatment for COPD

Outcomes

Primary Outcomes

To assess the difference in asthma related exacerbations

Asthma related exaceberation is defined as any asthma related emergency department visit, or inpatient visit or oral corticosteroid dispensing.

Time frame: 90 days post index

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.